ABSTRACT
Background Previous results from observational, interventional studies and in vitro experiments suggest that certain micronutrients have anti-viral and immunomodulatory activities. In particular, it has been hypothesized that zinc, selenium, copper and vitamin K1 have strong potential for prophylaxis and treatment of COVID-19.
Objectives We aimed to test whether genetically predicted Zn, Se, Cu or vitamin K1 levels have a causal effect on COVID-19 related outcomes: risk of infection, hospitalization and critical illness.
Methods We employed two-sample Mendelian Randomization (MR) analysis. Our genetic variants derived from European-ancestry GWAS reflected circulating levels of Zn, Cu, Se in red blood cells as well as Se and vitamin K1 in serum/plasma. For the COVID-19 outcome GWAS, we used infection, hospitalization or critical illness. Our inverse-variance weighted (IVW) MR analysis was complemented by sensitivity analyses: more liberal selection of variants at genome-wide subsignificant threshold, MR-Egger and weighted median/mode tests.
Results Circulating micronutrient levels show limited evidence of association with COVID-19 infection with odds ratio [OR] ranging from 0.97 (95% CI: 0.87-1.08, p-value=0.55) for zinc to 1.07 (95% CI: 1.00-1.14, p-value=0.06) – ie. no beneficial effect for copper, per 1 SD increase in exposure. Similarly minimal evidence was obtained for the hospitalization and critical illness outcomes with OR from 0.98 (95% CI: 0.87-1.09, p-value=0.66) for vitamin K1 to 1.07 (95% CI: 0.88-1.29, p-value=0.49) for copper, and from 0.93 (95% CI: 0.72-1.19, p-value=0.55) for vitamin K1 to 1.21 (95% CI: 0.79-1.86, p-value=0.39) for zinc, respectively.
Conclusions This study does not provide evidence that supplementation with zinc, selenium, copper or vitamin K1 can prevent SARS-CoV-2 infection, critical illness or hospitalization for COVID-19.
Competing Interest Statement
Tom R Gaunt receives funding from Biogen for unrelated research.
Funding Statement
This research was funded by the UK Medical Research Council (mc_uu_00011/4) and carried out in the MRC Integrative Epidemiology Unit.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
All exposure data described in the article is provided in the supplementary tables. All outcome data is available from COVID-19 HGI website: https://www.covid19hg.org/results/r5/
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All exposure data described in the article is provided in the supplementary tables. All outcome data is available from COVID-19 HGI website: https://www.covid19hg.org/results/r5/ Code for statistical analyses is available on: https://github.com/marynias/covid19
List of abbreviations
- GWAS
- Genome wide association study
- MR
- Mendelian Randomization
- RCT
- Randomized control trial
